EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Inclusion Criteria: * Biologic males or females * 18 - 99 years of age * Histologically confirmed cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or other cutaneous malignancy for which lymphoscintigraphy and sentinel lymph node biopsy has been recommended. Exclusion Criteria: * Known allergy or intolerance to EMLA cream, lidocaine, prilocaine, or any other local anesthetic * History of adhesive allergy * Contraindication to Tc99 injection for sentinel lymph node mapping * Incarcerated patients * Patients incapable of independently providing consent * Mucosal or genital lymphoscintigraphy site * Pregnancy * Participant self-declared or Ohio State University (OSU) medical chart listing chronic pain as a pre-existing diagnosis * Participants with chronic pain as defined by the Centers for Disease Control and Prevention (CDC):"pain lasting 3 months or more that can be caused by a disease or condition, injury, medical treatment, or unknown reason" excluding those with stable co-morbid conditions such as peripheral neuropathy, fibromyalgia, arthritis, and cancer-related pain who do not require narcotics. Patients who require narcotics at any time within the 7-day period leading up to the procedure